A Randomized Clinical Study to Evaluate the Impact of Injection Site (Thigh vs Abdomen) on the Pharmacokinetics and Relative Bioavailability of Subcutaneously Injected MK-6194 in Healthy Adult Participants
Latest Information Update: 24 Oct 2024
Price :
$35 *
At a glance
- Drugs MK 6194 (Primary)
- Indications Atopic dermatitis; Systemic lupus erythematosus; Ulcerative colitis; Vitiligo
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 24 Oct 2024 New trial record